moatshark My

All holdings

Alnylam Pharmaceuticals

ALNY

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
2
In their latest 13F (Q3 2026)
See who
Value held
$589m
Combined value at quarter end
Last quarter
1 bought
1 sold or trimmed
Fund portfolios
1
Funds holding it
See which
Price at Q2 ’26 end
$301.03
-9.0% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+13.2%Q3 ’24
-14.4%Q4 ’24
+14.8%Q1 ’25
+20.8%Q2 ’25
+39.8%Q3 ’25
-12.8%Q4 ’25
-16.8%Q1 ’26
-9.0%Q2 ’26
Q3 ’24: +13.2%; Q4 ’24: -14.4%; Q1 ’25: +14.8%; Q2 ’25: +20.8%; Q3 ’25: +39.8%; Q4 ’25: -12.8%; Q1 ’26: -16.8%; Q2 ’26: -9.0%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

2Q4 ’23
2Q1 ’24
2Q2 ’24
2Q3 ’24
2Q4 ’24
2Q1 ’25
2Q2 ’25
3Q3 ’25
2Q4 ’25
2Q1 ’26
2Q2 ’26
0Q3 ’26
Q4 ’23: 2; Q1 ’24: 2; Q2 ’24: 2; Q3 ’24: 2; Q4 ’24: 2; Q1 ’25: 2; Q2 ’25: 2; Q3 ’25: 3; Q4 ’25: 2; Q1 ’26: 2; Q2 ’26: 2; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Alnylam Pharmaceuticals.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Alnylam Pharmaceuticals
Dodge & Cox0.3%$589m$589mAdded +1.4%41 qtrs
Horizon Kinetics0.0%$653k$653kTrimmed -4.6%25 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Alnylam Pharmaceuticals
Bought or soldFiling
2 Oct 2026Supran BryanEVP, CLO and Secretary▼ Sold1,758$226.88$399kForm 4

About the company

Sector
Health care · Pharmaceutical Preparations
Financial year ends
31 December
Shares outstanding
134m at 24 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

2013
2015
$89.9m2017
$220m2019
$844m2021
$1.8bn2023
$3.7bn2025
2013: not held; 2014: not held; 2015: not held; 2016: $47.2m; 2017: $89.9m; 2018: $74.9m; 2019: $220m; 2020: $493m; 2021: $844m; 2022: $1.0bn; 2023: $1.8bn; 2024: $2.2bn; 2025: $3.7bn
Alnylam Pharmaceuticals revenue and net income by year
YearRevenueNet income
2025$3.7bn$314m
2024$2.2bn−$278m
2023$1.8bn−$440m
2022$1.0bn−$1.1bn
2021$844m−$853m
2020$493m−$858m
2019$220m−$886m
2018$74.9m−$761m
2017$89.9m−$491m
2016$47.2m−$410m
2015–−$290m
2014–−$360m
2013–−$89.2m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

In fund portfolios

US-registered funds run by these managers that hold Alnylam Pharmaceuticals, from their latest N-PORT filings.

Funds holding Alnylam Pharmaceuticals
Dodge & Cox Global Stock FundDodge & Cox0.4%$48.7m30 Jun 2026